We harness our technology to deliver novel microbiome-focused phage
therapeies to alleviate conditions such as IBD, cancer, and skin disorders.
Acne-prone Skin BX001
BX002 is a customized phage cocktail aimed at eradicating proprietary bacterial targets associated with the onset of IBD. These targets, discovered by Dr. Kenya Honda, Professor of Microbiology and Immunology at Keio University School of Medicine, were shown to be pro-inflammatory and may have a role in the onset and aggravation of IBD (Atarashi et al., Science, 2017 https://www.ncbi.nlm.nih.gov/pubmed/29051379).
BX002 offers a groundbreaking approach for treating IBD as it targets a possible underlying cause for the disease, whereas existing medications offer only symptomatic relief to this chronic, lifelong condition. BiomX plans to file an IND application with the US FDA for BX002 in 2019. Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, affect as many as 1.6 million Americans, most of whom are diagnosed before age 35. Medications today offer symptomatic relief to these chronic, lifelong conditions, but do not cure them. IBD can significantly affect a patient’s quality of life and may have a high financial burden.
BX003 is a customized phage cocktail being developed against specific strains of Klebsiella pneumoniae (Kp) that were isolated from the gut microbiome of PSC patients and were shown to disrupt the epithelial barrier (cause a ‘leaky gut’) and translocate outside the gut. These targets, which potentially affect progression of the disease, were discovered by Professor Takanori Kanai of Keio University School of Medicine and were published in Nature Microbiology (https://www.nature.com/articles/s41564-018-0333-1)
Harnessing Synthetic Biology